S
udden cardiac death (SCD) is defined as an unexpected fatal event occurring within 1 hour after the onset of symptoms in an apparently healthy subject or patients with an underlying cardiac disease not severe enough to predict such a fatal outcome. 1 About 400 000 SCD occur every year in the United States, 2 more than 75% in patients with coronary artery disease. [3] [4] [5] The most common pattern leading to SCD is acute arterial thrombus formation initiating fatal ventricular arrhythmias 3 ; indeed, in several postmortem studies, acute thrombosis was identified in the majority of coronary arteries examined. 6 -8 Tissue factor (TF), as the main initiator of the coagulation cascade, is essential for arterial thrombus formation. 9 TF expression in endothelial cells is induced by different inflammatory mediators including tumor necrosis factor (TNF)-␣, 10 interleukin (IL)-1␤, 11 or histamine, 12 and, consistent with these observations, TF expression is upregulated in atherosclerotic plaques of patients with unstable angina and myocardial infarction. 13 Amiodarone [2-butyl-3-(3,5-diiodo-4-diethylaminoethoxybenzoyl)-benzofuran] is widely used for the treatment of atrial and ventricular arrhythmia, 14 -16 even though it was originally introduced as a potent coronary vasodilator. 17, 18 Belonging to class III antiarrhythmic drugs, 19 amiodarone is a potassium channel inhibitor in cardiac myocytes and is known, despite its clinical effectiveness, for its low proarrhythmic potential. In a large meta-analysis of 13 randomized trials of prophylactic amiodarone treatment in patients with symptomatic compensated congestive heart failure (ejection fraction Յ40%) or after acute myocardial infarction (with variable ejection fraction), amiodarone reduced overall rates of SCD by 29% resulting in a 13% reduction in total mortality. 20 To date it is not known whether the beneficial effects attributed to amiodarone are solely attributable to its electrophysiological properties or whether other mechanisms, such as inhibition of arterial thrombus formation, might be involved as well. This study was therefore designed to investigate the effect of amiodarone on thrombus formation and TF, the key initiator of the coagulation cascade.
Materials and Methods
For the detailed Materials and Methods please see the supplemental Materials and Methods (available online at http://atvb.ahajournals. org). Briefly, C57Bl/6 mice were treated with amiodarone (80 mg/kg with an intraperitoneal injection every 24 hours for 7 days) or vehicle (1.43% Tween 80, 0.29% benzyl alcohol), respectively. The photochemical injury model was performed 24 hours after the last application as described previously. 21 The concentration of amiodarone and MDEA was measured in mouse plasma and aorta by high-performance liquid chromatography (HPLC). PTT, aPTT, tail bleeding time, and platelet number were determined to investigate systemic coagulation parameters.
Human aortic endothelial cells (HAECs; Clonetics, Allschwil, Switzerland) and human aortic vascular smooth muscle cells (HAVSMCs; Clonetics) were cultured as described. 22 Protein expression was determined by Western blot analysis, and RNA by real-time polymerase chain reaction (PCR) after isolation with TRIzol Reagent (Invitrogen). Further, TF activity was measured with a colorimetric assay (American Diagnostica).
Results

Amiodarone Inhibits TF Activity and Arterial Thrombosis In Vivo at Clinically Relevant Plasma and Tissue Concentrations
Mice were treated with amiodarone (80 mg/kg body weight, intraperitoneal injection) or vehicle every 24 hours for 7 days. Amiodarone and MDEA concentrations were determined in mouse plasma as well as in thoracic aorta. Amiodarone plasma concentration was 1.53Ϯ0.17 mol/L (1.05Ϯ0.12 mg/L), and tissue levels reached a concentration of 64.08Ϯ7.59 mol/g (43.69Ϯ5.18 g/g) (nϭ4; Figure 1A and 1B Figure 1A and 1B). Vehicle-treated mice developed carotid artery thrombosis within a mean occlusion time of 39.6Ϯ3.0 minutes, whereas amiodarone-treated mice occluded within a mean time period of 83.3Ϯ12.1 minute (nϭ7; PϽ0.005; Figure  1C 
Amiodarone Inhibits TF Protein Expression and Surface Activity
HAECs were stimulated with TNF-␣ (5 ng/mL) or thrombin (1 U/mL) for 5 hours in the presence or absence of amiodarone. Amiodarone inhibited TNF-␣ and thrombin-induced TF protein expression in a concentration-dependent manner; a significant effect was observed at 3 mol/L, whereas the maximal effect occurred at 10 mol/L and reached more than 80% inhibition (TNF-␣: nϭ4; PϽ0.001; Figure 2A ; thrombin: nϭ4; PϽ0.05; Figure 2B ). Amiodarone blunted TNF-␣-induced TF protein expression throughout the time course from 1 to 5 hours after stimulation (nϭ4; PϽ0.01; Figure  2C ), and, consistent with its effect on TF expression, impaired TF surface activity (nϭ4; PϽ0.02; Figure 2D ). Amiodarone also inhibited TF protein expression in HAVSMCs (nϭ6; PϽ0.005; Figure 2E ). In contrast, amiodarone did not induce any changes in cell morphology, and no signs of toxicity were detected by LDH release for all concentrations applied (nϭ4; PϭNS; data not shown).
MDEA and AMWI Inhibit TF Protein Expression
MDEA, the major metabolite of amiodarone in vivo, 23 inhibited TF protein expression in TNF-␣-stimulated HAECs at 3 mol/L (nϭ4; PϽ0.02; Figure 3A ), whereas it was toxic at higher concentrations as determined by LDH release (nϭ4; PϽ0.001; data not shown). AMWI suppressed TF protein expression to a similar extent as amiodarone (nϭ5; PϽ0.05; Figure 3B ). No cell damage was detected by LDH release for all concentrations of AMWI (nϭ5; PϭNS; data not shown). 
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Amiodarone Does Not Affect TFPI
Neither basal nor TNF-␣-induced TFPI protein expression was affected by amiodarone (nϭ4; PϭNS; Figure 3C ).
Amiodarone Does Not Affect TF mRNA Expression
Real-time PCR revealed that TNF-␣ (5 ng/mL) induced TF mRNA expression within 1 hour (nϭ5; PϽ0.01; Figure 4A ). Amiodarone (10 mol/L) did not affect TF mRNA expression (nϭ5; PϭNS for each time point; Figure 4A ).
Amiodarone Does Not Affect Activation of MAP Kinases and NFB
TNF-␣ (5 ng/mL) induced a transient phosphorylation of the MAP kinases p38, extracellular signal regulated kinase (ERK), and JNK, with a maximal effect after 15 minutes of stimulation. Amiodarone did not alter MAP kinase activation (nϭ3; PϭNS for each time point; Figure 4B ). Similarly, activation of NFB, as determined by degradation of its inhibitor IB-␣, was not affected (nϭ3; PϭNS for each time point; Figure 4B ).
Amiodarone Inhibits TF Protein Translation
The effect of amiodarone on TF protein translation was assessed by a metabolic pulse labeling experiment using Figure 5A ). Unspecific binding of the immunoprecipitating antihuman TF antibody could be excluded using nonimmune IgG ( Figure 5A ). Because potassium is essential for protein synthesis 24 
Amiodarone Does Not Promote TF Protein Degradation
HAECs were stimulated with TNF-␣ (5 ng/mL) for 3 hours before addition of cycloheximide (5 ng/mL), amiodarone (10 mol/L), or both. TF protein expression remained stable under control conditions from 3 to 7 hours after stimulation (nϭ4; PϭNS versus TNF-␣ for each time point; Figure 5B ). Cycloheximide alone did not alter TF protein degradation (nϭ4; PϭNS versus TNF-␣ for each time point; Figure 5B ). Similarly, amiodarone did not affect TF protein degradation, neither alone (nϭ4; PϭNS versus TNF-␣ for each time point; Figure 5B ) nor together with cycloheximide (nϭ4; PϭNS versus TNF-␣ for each time point; Figure 5B ).
Discussion
This study shows that amiodarone, at clinically relevant concentrations, impairs thrombus formation, arterial TF activity, and total platelet number in vivo. Further, it demonstrates that amiodarone reduces TF surface activity and protein expression in human vascular cells by an inhibition of TF translation. These results reveal a novel antithrombotic pleiotropic action of amiodarone.
Patients receiving long-term amiodarone treatment (200 mg orally per day) exhibit plasma concentrations of amiodarone and MDEA averaging 1.70Ϯ0.63 mol/L (1.16Ϯ0.43 mg/L) and 1.48Ϯ0.53 mol/L (0.97Ϯ0.35 mg/L), respectively. 23, 26 Higher levels are observed with a dose of 600 mg per day averaging 5.08Ϯ2.20 mol/L (3.46Ϯ1.5 mg/L) for amiodarone and 4.26Ϯ1.78 mol/L (2.79Ϯ1.17 mg/L) for MDEA. 26, 27 After intravenous application of amiodarone, concentrations as high as 11.74 mol/L (8 mg/L) are observed. 28 Because of their lipophilic properties, both amiodarone and MDEA accumulate to high concentrations in various tissues; 26, 27, 29 indeed, in human myocardium, amiodarone and MDEA levels reach 12.3 to 22.9 mol/g (8.4 to 15.6 g/g), and 42.3 to 78.0 mol/g (27.7 to 51.1 g/g), respectively, and 10 times higher concentrations were measured in epicardial fat tissue (153.75 mol/g [105.0 g/g]). 27 Mice for the in vivo experiments were treated with amiodarone for 7 days to reach steady-state plasma and tissue levels of the drug. Mouse amiodarone plasma concentrations (1.53Ϯ0.17 mol/L [1.05Ϯ0.12 g/mL]) as well as in the aortic vessel wall (64.08Ϯ7.59 mol/g [43.69Ϯ5.18 g/g]) equal plasma and tissue levels in humans under chronic amiodarone therapy. Nevertheless, mouse plasma and tissue concentrations of MDEA were lower than those of amiodarone, which is in contrast to findings in humans, where comparable or even higher MDEA levels are observed. 23, 26 This observation is in line with previous studies and may be attributable to a different liver metabolism in the two species. 30, 31 Further, the amiodarone and MDEA concentrations applied in our in vitro study (1 to 10 mol/L) are within a clinically relevant range. Hence, the herein observed antithrombotic action of amiodarone may well represent an additional mechanism by which amiodarone reduces SCD.
TF is the key initiator of coagulation and therefore is an essential trigger for thrombosis. 32, 33 In fact, reducing TF expression impairs thrombus formation in vivo, thus underscoring this concept. 9 Plaque rupture, a frequent initial event in acute coronary syndromes, leads to the exposure of TF to the circulation resulting in acute thrombus formation. In addition, prothrombin is expressed by vascular smooth muscle cells 34 and exposed to the circulating blood under these conditions; once activated in response to TF-induced coagulation this vessel wall-derived prothrombin may well contribute to thrombus formation, underlying the central role of TF. To investigate arterial thrombosis in vivo, a photochemical vascular injury model was used as it is an established method to study TFdependent thrombus formation. 9 Mean occlusion time in amiodarone-treated mice was more than doubled, indicating that clinically relevant concentrations of amiodarone do indeed inhibit arterial thrombus formation in vivo. The reduced TF activity in mouse carotid artery indicates that amiodarone negatively regulates thrombus formation at least in part by inhibiting TF in vivo. Amiodarone is known to be a potent vasodilatator in veins and arteries. A contribution of such an acute effect to the increase in mean occlusion time can be excluded, because arterial thrombus formation after a bolus treatment with amiodarone did not reveal any difference as compared to the control group. Moreover, an involvement of the extrinsic and intrinsic pathway of the coagulation cascade could be ruled out as PTT and aPTT were not affected by amiodarone. Nevertheless, the reduced total platelet count suggests that platelets may contribute to the amiodarone-mediated antithrombotic effect.
To assess the relevance of the amiodarone effect in human cells, we treated human primary vascular cells with clinically relevant amiodarone concentrations. Indeed, amiodarone exhibited a consistent effect on TF activity as well as protein expression; furthermore, the unaltered expression of TFPI excludes a compensating effect of the impaired TF expression and therefore underlies the possibility of a potent antithrombotic property of amiodarone in humans, because the balance with TFPI, the physiological antagonist of TF, is critical for thrombus formation. 35 Amiodarone regulated TF protein expression at the translational level, because MAP kinase activation, TF mRNA expression, and TF protein degradation remained unaffected. This was confirmed by a metabolic pulse labeling experiment using [ 35 S]-methionine/cysteine as radioactive tracer. Besides its known antiarrhythmic properties, pleiotropic alterations of protein expression by amiodarone have been reported. 36 -38 A recent report described decreased expression of CACNA1C, the ␣-1C subunit of the L-Type calcium channel, at the posttranscriptional or translational level. 39 Amiodarone also interferes with mitochondrial metabolism and energy supply; 40,41 a similar mechanism could explain the impaired TF expression in endothelial cells, because protein translation is energy dependent. Ouabain, an established Na ϩ /K ϩ -ATPase inhibitor, is known to deplete intracellular potassium concentration in endothelial cells and in turn downregulates TF protein expression at the translational level. 24, 25 Such an effect can be excluded for amiodarone, because it does not affect intracellular potassium levels.
Dealkylation is the first step in degradation of amiodarone and results in the pharmacologically active metabolite MDEA which exhibits plasma levels comparable to amiodarone. 23 MDEA is known to exert toxic effects at lower concentrations than amiodarone. 42, 43 In line with these observations, 10 mol/L MDEA, but not amiodarone, was toxic for endothelial cells. At lower concentrations, MDEA impaired TF expression and may thus potentiate the antithrombotic effect of amiodarone. MDEA and amiodarone seem to be degraded further, because elevated excretion of free iodine has been observed in humans treated with amiodarone. 44 The free iodine is mainly responsible for changes in thyroid function resulting in hypo-or hyperthyroidism; 45, 46 nevertheless, the iodine is not essential for inhibition of TF protein expression, because amiodarone lacking iodine suppressed TF expression to a similar extent as amiodarone.
About 75% of all SCD are imputable to coronary artery disease. [3] [4] [5] The majority of them are triggered by ventricular arrhythmia, often caused by acute coronary events. 3 This is supported by evidence from autopsies, showing that the majority of SCD are associated to acute coronary thrombosis. 6 -8 Therefore, in patients with coronary artery disease, it seems likely that acute thrombus formation is the main initial event leading to SCD. In patients suffering from myocardial infarction or congestive heart failure, amiodarone reduced SCD by 29% and total mortality by 13%. 20 The present study suggests that amiodarone may decrease SCD not only by preventing ventricular arrhythmia, but also by inhibiting arterial thrombosis. Indeed, subgroup analysis of prophylactic amiodarone treatment did not reveal a greater effectiveness in patients with higher frequencies of ventricular arrhythmia, 20 which supports the observation of a antithrombotic pleiotropic effect of amiodarone contributing to the reduction of SCD.
In summary, the present study demonstrates that amiodarone, at clinically relevant concentrations, inhibits arterial thrombus formation by decreasing TF activity and platelet number in a mouse thrombosis model in vivo. A conserved effect was observed in human vascular cells where amiodarone inhibited TF activity and protein expression at the translational level. Because thrombosis is the main initial event leading to SCD in patients with coronary artery disease, these results reveal new possible insights with respect to the beneficial actions of amiodarone.
pooled and evaporated to dryness (Speed Vac, Savant Instruments Inc., Farmingdale, NY). To the residue was dissolved in 75µl of the mobile, and an aliquot of 50 µl was analyzed. Plasma (200 µl) was mixed with 0.1 ml 0.5 mM KH 2 PO 4 and extracted three times with 0.75 ml diethylether. The organic extracts were pooled and evaporated to dryness as described. The residue was dissolved in 100 µl of methanol, and an aliquot of 50 µl was used for HPLC.
PTT, aPTT, tail bleeding time, and blood cell counts
Prothrombin time (PTT) and activated partial thromboplastin time (aPTT) were assessed by the Start4 analyzer (Diagnostica Stago, France) with according reagents (Roche Diagnostics, Switzerland). Plasma from citrated blood (3.2% citrate 1/10) was extracted by 15 minutes centrifugation (2500g, 4°C), and stored immediately at -80°C until analysis. Tail bleeding time was assessed as described 23 . Briefly, after anesthetizing mice, the distal 4-mm segment of the tail was removed with a scalpel.
Bleeding was monitored by gently absorbing the blood with a filter paper at 15 second intervals without touching the wound. To count blood cells, whole blood was collected in heparin-coated tubes and analyzed by flow cytometry.
Cell Culture
Human aortic endothelial cells (HAECs; Clonetics, Allschwil, Switzerland) and human aortic vascular smooth muscle cells (HAVSMCs; Clonetics) were cultured as described 22 . Adhering HAECs were grown to confluence and rendered quiescent for . A melting curve analysis was performed after amplification to verify the accuracy of the amplicon. L28 RNA served as loading control.
TF activity
TF surface activity in HAECs and TF activity in mouse carotid artery tissue homogenates was analyzed using a colorimetric assay (American Diagnostica) 21 .
Cells were incubated at 37°C with human FVIIa and FX, allowing for the formation of TF/FVIIa complex at the cell surface. Left carotid arteries from amiodarone treated mice were homogenized in 50 µl lysis buffer (50 mmol Tris-HCl, 100 mmol NaCl, 0.1% Triton X-100 pH 7.4) before incubation. Conversion of FX to FXa was measured by the ability of FXa to cleave a chromogenic substrate. A standard curve was established with lipidated human TF to assure that the results were in the linear range of detection.
Metabolic labeling
